Last reviewed · How we verify
Individualization of first voriconazole maintenance doses
Individualization of first voriconazole maintenance doses is a Small molecule drug developed by University Hospital, Grenoble. It is currently FDA-approved.
Individualization of first voriconazole maintenance doses, developed by University Hospital, Grenoble, is a marketed product with a key composition patent expiring in 2028. The primary strength lies in its tailored dosing approach, which can enhance efficacy and safety. The primary risk is the lack of clear revenue data and key trial results, which may impact market adoption and competitive positioning.
At a glance
| Generic name | Individualization of first voriconazole maintenance doses |
|---|---|
| Sponsor | University Hospital, Grenoble |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Individualization of first voriconazole maintenance doses CI brief — competitive landscape report
- Individualization of first voriconazole maintenance doses updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI